Answers are grounded in this paper and cite their sources.
Studies have shown the messenger RNA (mRNA) vaccine against SARS-CoV-2 is safe in multiple sclerosis (MS), but the humoral response to the vaccine was markedly reduced in patients treated with fingolimod and ocrelizumab. We aimed to replicate these findings, test other disease-modifying treatments (DMTs), and investigate whether delaying anti-CD20 infusions can potentiate IgG production following vaccination.
No takes yet. Share an insight, caveat, or question.
Disanto et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: